Abstract 442P
Background
Modified FOLFIRINOX is the standard of care for advanced pancreatic cancer and has expanded application in biliary tract and colorectal cancers. Despite its efficacy, real world data suggests nearly 75% of patients are unable to maintain dose intensity leading to reduction in efficacy and survival. We proposed to evaluate the dose intensity (DI) and toxicity of patients planned for mFOLFIRINOX.
Methods
It is a retrospective analysis of medical records. All patients planned for mFOLFIRINOX between January 2017 and May 2022 were included. Demographic and disease details were collected. DI of each drug were calculated. Toxicity was recorded as per CTCAE v5.0. Serological, clinical and radiological response was recorded if available. Survival analysis was performed and data censored at last follow up.
Results
40 patients were included in analysis. Mean age was 51.5 years. 75% had pancreatic biliary cancer and 25% had colorectal cancer. 70% had stage IV cancer. ECOG PS was 0-1 in 75% of patients. All patients were planned at for initial dose reduction by 25%. Dose intensity was maintained only in 50% of patients. Relative DI (RDI) for oxaliplatin, 5FU, irinotecan and leucovorin was 38%,36%,41% and 39% respectively. The most frequent ≥ grade 3 toxicity was fatigue (75%). Grade 3 thrombocytopenia and Neutropenia was seen in 45% and 42% respectively. Febrile neutropenia was seen in 6 patients. No patients had any grade 4-5 toxicity. Only 50% of patients completed the planned therapy. The median time for delay in treatment 30 days. 32.5% had a radiological stable disease or better as their best response. Serological and clinical response was seen in 27.5% and 20% of patients respectively. The median PFS for pancreatic cancer was 240 days (95%CI:67.40-375.06) and for colorectal cancer was 252 days (95%CI:135.75-286.24).
Conclusions
Only 50% of patients completed the planned therapy with mFOLFIRINOX in our population. This has resulted in poor efficacy of the regimen.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Author.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
439P - Evaluating Ewing’s sarcoma as the prototype for cancer care in teenage and young adults (TYA): A single-center retrospective cross-sectional study
Presenter: Pradeep Kumar Kistampally
Session: Poster viewing 06
440P - Targeting KRAS<sup>G12C</sup>: Repurposing of potential therapeutics for the treatment of pancreatic ductal adenocarcinoma (PDAC)
Presenter: EVA RAHMAN KABIR
Session: Poster viewing 06
441P - Malignant diseases diagnosed in people living with HIV in Japan
Presenter: Kenju Ando
Session: Poster viewing 06
444P - Incidence of cancer diagnosis and cancer care before and after the COVID-19 pandemic in French Polynesia TEAHUPOO study
Presenter: Elodie HIRIGOYEN
Session: Poster viewing 06
445P - Development of a simple and objective prognostication model in patients with advanced solid malignant tumor treated with immune checkpoint inhibitors: A pan-cancer analysis
Presenter: Yuto Matsushita
Session: Poster viewing 06
446P - Impact of previous immunotherapy on chemotherapy efficacy in metastatic melanoma
Presenter: Meiyu Fang
Session: Poster viewing 06
447P - Clinical characteristics of 21 patients with type 1 diabetes mellitus related to immune checkpoint inhibitors
Presenter: Haruna Kameoka
Session: Poster viewing 06
448P - Prevalence of thyroid dysfunction, diabetes, and impact of palliative chemotherapy in advanced metastatic cancer patients: Prospective data from LMIC
Presenter: Amit Sehrawat
Session: Poster viewing 06
449P - The study of androgen receptor status in triple negative breast cancer patients at Medical Oncology Department, Yangon General Hospital (YGH)
Presenter: Khin Mu
Session: Poster viewing 06
450P - Are grade III well-differentiated neuroendocrine tumours a unique clinic-pathological entity?
Presenter: Jahnavi Kalvala
Session: Poster viewing 06